RT Journal
A1 Desai S, Brinker A, Swann J, Iyasu S
T1 Sitagliptin-associated drug allergy: Review of spontaneous adverse event reports
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2010
FD July 12
VO 170
IS 13
SP 1169
OP 1171
DO 10.1001/archinternmed.2010.188
UL http://dx.doi.org/10.1001/archinternmed.2010.188
AB 
Sitagliptin (Januvia; Merck and Co Inc, Whitehouse Station, New Jersey) was the first dipeptidyl peptidase-4 inhibitor (DPP-4) to gain approval from the Food and Drug Administration (FDA) in October 2006 for the treatment of type 2 diabetes mellitus.1 In October 2007, approved labeling for sitagliptin was updated to note the appearance of spontaneous adverse event reports of hypersensitivity reactions (ie, anaphylaxis, angioedema, serious skin reactions) and noted that most reported events occurred within the first 3 months after initiation of treatment, including some following the first dose.1 The objective of our study was to construct a case series of sitagliptin-associated allergic reactions within an empirical model for the assessment of events consistent with drug allergy.